Stryker: Q3 Earnings Snapshot

Stryker Corp. (SYK) reported Q3 profit of $753M, or $1.96 per share, missing analyst estimates of $3.56 per share. Revenue was $6.52B, also below expectations. The company forecasts full-year earnings of $14.80-$14.90 per share, according to Zacks Investment Research.

Original reporting
Published Oct 29, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stryker: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$SYKBearishMed
01

Why it matters

Because it includes both the quarter’s EPS/revenue versus expectations and a specific full-year EPS range, it can drive immediate earnings estimate revisions and near-term positioning in SYK.

02

Market read

Traders can update SYK’s earnings expectations using the reported Q3 miss and the stated FY EPS range.

03

What to watch

The article does not break out segment performance, margins, or cash flow, so traders may overreact to headline EPS/revenue without knowing the underlying drivers.

Relevance 8/10Novelty 7/10Timing: reported Thursday after the quarter closed, before/around the next trading session

Background

The piece is an AP-generated earnings snapshot for Stryker’s Q3 results, referencing Zacks consensus estimates.

Company-level read

Ticker impact

$SYKBearishMedium confidence
Context

Stryker reported Q3 profit of $1.96 per share and adjusted EPS of $3.52, both below Zacks/Street expectations, and guided FY EPS to $14.80-$14.90.

Expected impact

Likely downward pressure as the market digests the EPS and revenue misses and compares the FY guidance range to expectations.

Evidence & confidence

The article provides the company’s own Q3 EPS and revenue versus consensus and a specific full-year EPS range, which are direct inputs to earnings revisions and valuation.

Market effects

A large medical device name missing on EPS and revenue can weigh on near-term sentiment for medtech earnings momentum, though the article does not provide sector-wide data.

Limited, primarily affects US medtech sentiment rather than a broad regional macro move.

Moderate for global medtech sentiment due to Stryker’s scale, but no cross-border catalysts are mentioned.

Counterpoint

The guidance range is still provided and may be viewed as stable or acceptable if investors expected a larger cut; the miss could be partially offset by confidence in full-year delivery.

Key entities

  • Stryker Corp.

    Medical device maker reporting Q3 profit, adjusted EPS, revenue, and full-year earnings guidance.

  • Zacks Investment Research

    Provides the analyst consensus estimates cited in the article for EPS and revenue.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.